The third booster vaccine Moderna from COVID-19 is recommended by the FDA for a part of the population
Shares of Moderna (MRNA), down 23.6% over the past month, rose 3.2% on Thursday and 2.3% in the premarket on Friday amid good news about the FDA commission’s support for the COVID-19 booster vaccine.
On Thursday, the Committee of the US Food and Drug Administration (FDA) unanimously voted to recommend the use of a third booster dose of the Moderna vaccine against Covid-19 among people 65 years and older and in high-risk individuals. Final approval in a few days.
The booster vaccine from Moderna will be used only for people who received two doses of the Moderna vaccine at least six months ago. The company also previously announced the high results of its booster vaccine in protection against the Delta strain.
Johnson & Johnson (JNJ) also expects the FDA Commission to approve its booster vaccine on Friday.
Last month, the FDA approved using an alternative booster vaccine against coronavirus from Pfizer (PFE) and BioNTech (BNTX). Moderna and Pfizer/BioNTech vaccines are vaccines based on informational RNA.
Shares of Pfizer and BioNTech have fallen by 6.9% and 29.5% over the past month. The claims were affected by reports of a decrease in the incidence of COVID-19 Delta and news in early October about the filing of an application for FDA approval of the first pill coronavirus produced by Merck (MRK).
Although booster doses of Moderna are not yet allowed, people with certain immunodeficiency conditions can receive a third dose of the Moderna vaccine. According to the Centers for Disease Control and Prevention in the United States (CDC), 1.5 million people in the United States have already received the third dose of Moderna.
Israeli government organizations have previously stated that Pfizer’s COVID-19 booster vaccines made it possible to quickly stop the spread of the Delta strain in the country.
The Committee is skeptical about booster vaccines for people under 65 years of age since little data proves the need and safety of use in this group.
The news about the potential imminent approval of booster vaccines from Moderna is positive for the company, indicating the possibility of selling millions of vaccines. In addition, the White House announced in August that it was planning a large-scale COVID third vaccination campaign pending FDA and CDC approval.
However, some analysts believe that may already embed the potential benefits from the sale of Moderna booster vaccines in the current stock valuation. Shares of Moderna have risen by 217.7% since the beginning of 2021.
In the United States, the Delta strain surge has already begun to weaken. For example, the average number of daily COVID-19 cases in seven days fell by 12% compared to the previous week, and the average number of daily deaths in seven days decreased by 5%.
However, this still amounts to more than 1,250 deaths from COVID-19 per day, primarily among the unvaccinated.
